|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation显示文摘 | Abhijeet Waghray Bengi Balci Galal El‐Gazzaz Richard Kim Robert Pelley KV Narayanan Menon Bassam Estfan Carlos Romero‐Marrero Federico Aucejo | 2013 | Clin Transplant2013，，4： | 3 |
| 2 | Epstein-Barr virus-associated smooth muscle tumors in immunocompromised patients:Six case reports显示文摘BACKGROUND Epstein-Barr virus associated smooth muscle tumor(EBV-SMT)is a rare oncological entity.However,there is an increasing incidence of EBV-SMTs,as the frequency of organ transplantation and immunosuppression grows.EBV-SMT diagnosis relies on histopathology and immunochemical staining to distinguish it from post-transplant lymphoproliferative disorder(PTLD).There is no clear consensus on the treatment of EBV-SMTs.However,surgical resection,chemotherapy,radiation therapy,and immunosuppression reduction have been explored with varying degrees of success.CASE SUMMARY Our case series includes six cases of EBV-SMTs across different age groups,with different treatment modalities,adding to the limited existing literature on this rare tumor.The median latency time between immunosuppression and disease diagnosis is four years.EBV-SMTs present with variable degrees of aggressiveness and seem to have worse clinical outcomes in patients with tumor multiplicity and worse immunocompetency.CONCLUSION It is imperative to continue building on this knowledge and keeping EBV-SMTs on the differential in immunocompromised individuals. | Afshin A Khan Bassam N Estfan Anirudh Yalamanchali Djibril Niang Erica C Savage Clifton G Fulmer Hailey L Gosnell Jamak Modaresi Esfeh | 2022 | World Journal of Clinical Oncology2022，13，6： | 2 |
| 3 | Sorafenib in advanced hepatocellularcarcinoma : hypertensions as potential surrogate for efficacy 显示文摘 | Estfan B Byrne M Kim R | 2013 | Am J Clin Oncol2013，36，4： | 1 |
| 4 | Errors in Opioid Prescribing: A Prospective Survey in Cancer Pain显示文摘 | Philip E. Shaheen Susan B. LeGrand Declan Walsh Bassam Estfan Mellar P. Davis Ruth L. Lagman Mohammad Riaz Bushra Cheema | 2010 | Journal of Pain and Symptom Management2010，，4： | 1 |
| 5 | Symptom Man-agement:An Important Part of Cancer Care显示文摘 | Shoemaker L K Estfan B Induru R | 2011 | Clere Clin JMed2011，78，1： | 1 |
| 6 | Errors in Opioid Prescribing: A Prospective Survey in Cancer Pain显示文摘 | Philip E. Shaheen Susan B. LeGrand Declan Walsh Bassam Estfan Mellar P. Davis Ruth L. Lagman Mohammad Riaz Bushra Cheema | 2010 | Journal of Pain and Symptom Management2010，，4： | 1 |
| 7 | Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy显示文摘 | Estfan B Byrne M Kim R | 2013 | Am J Clin Oncol2013，36，4： | 1 |
| 8 | 血清白蛋白水平预测肝门部胆管癌患者的生存显示文摘背景与目的:肝门部胆管癌是一种极具威胁的恶性肿瘤,其发生率随地域及其他危险因素的不同而有所差异,其快速进展的疾病特点及难以早期诊断的现状使相当数量的患者无法得到根治性治疗。本研究的目的是明确影响肝门部胆管癌患者总体生存的预后因素。方法:收集2003-2013年间经组织学证实的成人肝门部胆管癌患者,评估其预后影响因素,评估变量包括入院时人口学资料、实验室指标、症状及影像学特征。结果:116例经病理诊断的肝门部胆管癌患者纳入研究。血清白蛋白>3.0 g/dL(P<0.01)、CA19-9200 U/mL(P=0.03)、癌胚抗原10μg/L(P<0.01)、有肝硬化病史(P<0.01)或有糖尿病病史(P=0.02)者,其总体生存时间延长。其中血清白蛋白>3.0 g/dL是一项独立的预后保护因素(HR=0.31,95%CI:0.14~0.70),可以得到44周的生存获益。结论:本研究是目前对于肝门部胆管癌预后因素的最大宗病例分析。血清白蛋白>3.0 g/dL是一项独立的预后指标,可以显著延长生存期。 | Abhijeet Waghray Anastasia Sobotka Carlos Romero Marrero Bassam Estfan Federico Aucejo KV Narayanan Menon | 2017 | Gastroenterology Report2017，5，1： | 1 |
| 9 | Symptom management: an important part of cancer care 显示文摘 | Shoemaker LK Estfan B Induru R | 2011 | Cleve Clin J Med2011，78，1： | 1 |
| 10 | 接受术后化疗的炎性肠病相关结直肠癌患者的复发率与生存率:一项比较研究显示文摘背景与目的:炎性肠病(IBD)患者具有一定结直肠癌发生风险。研究显示,IBD相关结直肠癌与非IBD相关结直肠癌在肿瘤发生机制和组织形态学上存在差异,提示其肿瘤行为和治疗反应也可能有所不同。我们旨在比较接受术后化疗IBD相关与非IBD相关的结直肠癌患者肿瘤复发及生存率的差异。方法:检索Cleve?land临床中心结直肠癌数据库,筛选出1994-2010年间的65例IBD相关结直肠癌且接受了术后辅助化疗的患者,排除21例临床资料不完整者。按照年龄、手术目的、肿瘤部位、肿瘤病理分级、AJCC分期和T分期,对IBD相关和非IBD相关的结直肠癌患者进行1:4的病例匹配分组。分别采用竞争风险模型和Cox回归模型来评估IBD对无病生存和总体生存的影响。结果:44例IBD相关和176例非IBD相关的结直肠癌患者完成匹配。在IBD组患者中,29例(66%)为溃疡性结肠炎,14例(19%)为克罗恩病,1例(2%)诊断为不确定型肠炎。IBD平均诊断年龄为(28.1±14.5)岁,IBD诊断至结直肠癌治疗的平均间期为(21.5±12.6)年。10例(23%)IBD组患者出现了肿瘤复发,而非IBD组则有34例(19%)复发(P=0.074)。IBD组与非IBD组患者无瘤生存率(HR=0.60;95%CI:0.35~1.05;P=0.074)和总体生存率(HR=0.87;95%CI:0.54~1.4;P=0.58)的差异均无统计学意义。结论:接受术后化疗的IBD相关结直肠癌患者,其复发率与生存率与非IBD相关结直肠癌患者相当。有必要行进一步的前瞻性研究来证实这些发现,以指导治疗决策。 | Mohannad Dugum Jingmei Lin Rocio Lopez Bassam Estfan Elena Manilich Luca Stocchi Bo Shen Xiuli Liu | 2017 | Gastroenterology Report2017，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员